Amyris, Inc., an Emeryville, Calif.-based vertically integrated biomanufacturing company, has announced that it will acquire Oobli Inc., a Davis, Calif.-based developer of fermentation-derived sweet proteins. Amyris described Oobli as the leading sweet protein innovator, whose ingredients are designed to help food and beverage brands reduce sugar without sacrificing taste.
The acquisition is intended to bring together Amyris’s scientific capabilities and manufacturing depth with Oobli’s expertise in protein fermentation. Amyris said the move follows its expansion of manufacturing capacity earlier this year at its advanced fermentation facility in Barra Bonita, Brazil, and represents a strategic commercial and technology expansion. The company expects the combination to accelerate its presence in protein- and peptide-based solutions across end markets.
Complementary platforms
“In Oobli, we see a commercial and technology platform that is a great complement to our own,” Amyris Chief Executive Officer Kathy Fortmann said in the announcement. She added that Oobli is positioned to change how sweetness reaches the market, and that Amyris aims to use its commercial scale and resources to accelerate that effort.
Fortmann also said that combining Oobli’s protein expertise with Amyris’s strain engineering, manufacturing scale and commercial capabilities could broaden the company’s capabilities in food and beverage, personal care, flavor and fragrances, agriculture and other markets.
Oobli’s commercial portfolio of sweet proteins is expected to be the first to benefit from the combined platform. Oobli has spent the past decade refining a fermentation process to produce sweet proteins that occur naturally in rare fruits and berries found near the equator.
How the proteins work
According to Oobli, sweet proteins are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein. The company says this can deliver sweetness without gut disruption or blood sugar spikes.
The portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, known scientifically as brazzein, monellin and thaumatin, respectively. Oobli says the ingredients have FDA GRAS status as an ingredient and are FEMA GRAS-affirmed for use as a natural flavor.
Oobli is targeting demand driven by growing consumer awareness of metabolic health and sugar reduction. The company says sweet proteins can be used across sports and nutrition, dairy, beverages, chocolate, bakery and confectionery products.
Scale and customer continuity
“At Oobli, we have always believed there was a better way to deliver the sweet taste consumers love, without the trade-offs to health and our environment,” Oobli Chief Executive Officer Ali Wing said. She said joining Amyris would give Oobli the scale and resources to pursue its ambition of making sweet proteins a global standard for sweetness solutions.
Amyris’s Fortmann said biomanufactured solutions succeed when they align with consumer demand and market needs, and that Oobli’s platform is intended to address sweet taste, sugar reduction and clean label goals at the same time. She welcomed the Oobli team into the Amyris family and cited potential synergies between the two platforms.
The acquisition is expected to close in the coming weeks. Amyris said all existing customer commitments and brand partnerships will continue to be honored without interruption as Oobli’s sweet protein portfolio expands within the company.
